Figure 4From: Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancerKaplan-Meier analysis of overall survival in specific patient subgroups. (a) Overall survival rate for patients with methylated FBXW7/hCDC4-β promoter was significantly higher than that for patients in the unmethylated group in lymph node positive patients from cohort 1 (log rank test, P = 0.017). (b) Overall survival for patients from cohort 2 showed a similar trend as patients in cohort 1 but was not statistically significant (log rank test, P = 0.72). (c) Patients with methylated FBXW7/hCDC4-β promoter and p53 mutation have improved survival compared to patients with p53 mutation and unmethylated FBXW7/hCDC4-β promoter in cohort 2 (log rank test, P = 0.048).Back to article page